The index of global left ventricular function (LV IGF) is an imaging marker with pronounced prognostic properties in relation to the development of adverse cardiovascular events and death, determined on the basis of data from both magnetic resonance imaging (MRI) of the heart and echocardiographic examination (EchoCG). Companion indicator (companion) LV IGF (LV IGFC) is a marker obtained from the average quadratic value of the sum of the impact and global LV volume, designed to overcome the limitations of LV IGF due to its calculation formula.

The aim. To evaluate the prognostic significance of LV IGF and its companion in patients aged 60 years and older with CHF and type 2 diabetes mellitus observed in outpatient settings.

Material and methods. The study included 215 outpatient patients: 110 (51.2%) men and 105 (48.8%) women aged 72 (67; 78) years with CHF IIa–III stage II–IV FC. And LVH (in %) was calculated using the formula: EG LV = (KDO LV–CSR LV)/[0.5=(UP TO LV+CSR LV)+(MMLJ/1.05)]=100. IGFC LJ = {(KDO LJ-CSR LJ)2+[0.5×(BDO LJ+CSR LJ)+(MMLJ/1.05)]2}0.5. The duration of the observation period was 29 (20; 36) months.

Results. LV IGF as a whole amounted to 20.6 (16.9; 23.2)%. LV IGF as a whole amounted to 313.8 (262.8; 400.0) ml. Depending on the presence or absence of DM, patients were divided into two groups: 68 patients with DM (group 1); 147 patients without DM (group 2). During the follow–up period of 29 (20; 36) months, 122 (56.7%) patients were hospitalized: in group 1–32 out of 68 (47.1%) patients; in group 2–90 out of 147 (61.2%) patients. The threshold value of LV IGF for predicting hospitalization due to CVD decompensation in group 1 patients was 21.4% or lower (area under the curve [PPK] 0.677±0.065, 95% CI 0.549–0.805, p=0.012; sensitivity 68.8%, specificity 61.1%); LV IGFC –  300.3 ml or more (PPK 0.666±0.067, 95% CI 0.535–0.797, p=0.019; sensitivity 62.5%, specificity 61.1%). There was a high rate of hospitalization due to CVD decompensation in group 1 with LV IGF of 21.4% or less (among patients with LV IGF of ≤21.4%, 59.5% of patients were hospitalized, more than 21.4% –32.3%) (OR 3.08, p<0.05); with LV IGFC of 300.3 ml or more (among patients with LV IGFC ≥300.3 ml, 58.8% of patients were hospitalized, less than 300.3 ml –  35.3%) (OR 2.62, p>0.05).

Conclusion. The threshold value of LV IGF for predicting decompensation of cardiovascular disease with subsequent hospitalization in patients 60 years and older with CHF and DM was ≤21.4%; LV IGF was ≥300.3 ml. The data obtained allow us to consider LV IGF, LV IGFC, as well as their combination as markers of an unfavorable prognosis in older patients with CHF and DM at the outpatient stage.

Introduction. The contribution of type 2 diabetes mellitus (type 2 diabetes) and cardiovascular diseases (CVD) to the increase in disability and mortality rates worldwide continues to grow steadily. Currently, the main focus is on the problem of atherosclerotic cardiovascular diseases (ACCD) in DM, while the manifestations of cardiac arrhythmias (LDC) in conditions of carbohydrate metabolism disorders have not been sufficiently studied.

The purpose of the study. To analyze and compare laboratory, instrumental and objective indicators in patients with type 2 diabetes mellitus (type 2 diabetes mellitus) and without, who have a history of cardiac arrhythmias (LDC).

Materials and methods. 103 patients with LDC (52 men and 51 women) were examined. 2 groups were formed: the main group – patients with LDC and type 2 diabetes (n=51) (group 1), the control group –  patients with LDC without diabetes (n=52) (group 2). A comparative analysis of laboratory-instrumental and clinical-anamnestic data in the groups was performed. Statistical data processing was performed using the statistical software package "Excel" ("Microsoft"), the program "Statistica 10" ("Statsoft Inc"). The value of p <0.05 was taken as the significance level. The reliability of the differences between the groups was determined using the Mann-Whitney U-test, and the correlation analysis was carried out using the Spearman criterion.

Results. The average age of the general group was 67[18;97] years, patients with type 2 diabetes 69 [53;93] years, patients without diabetes 65 [18;97] years. According to the performed regression analysis, it was found that DM in patients was associated with the detection of atrial fibrillation (OR 2.69 (95% CI 1.076;6.71), p=0.034), in particular, its constant form (p=0.025, coefficient. Kramer's V = 0.33), as well as with the presence of supraventricular extrasystole (NJES) (OR 0.235 (95%CI 0.09;0.59), p=0.002, coefficient. Kramer's V = 0.311). At the same time, there was no significant association of DM with the presence of paroxysmal and persistent forms of atrial fibrillation, atrial flutter (TP), BLNPG, AV block, CA block, ventricular extrasystole, supraventricular tachycardia (NVT) and SSSI.

When evaluating the functional parameters of the myocardium according to Echo-K G data, it was found that in the main group, compared with the control group, significant (34% vs. 27%) and pronounced (18% vs. 6%) pulmonary hypertension were more common, but the difference was not statistically significant (p>0.05).

When assessing the structural and geometric parameters of the myocardium, it was found that concentric myocardial hypertrophy was more common in the main group (22% vs. 15%), and in the control group –  concentric myocardial remodeling (14% vs. 25%), (p>0.05).

Conclusions. DM is a significant risk factor for a more severe course of LDC, in particular atrial fibrillation and supraventricular ectopias. In this regard, it is of fundamental importance to control carbohydrate metabolism and prevent risk factors for cardiovascular diseases in order to preserve the basic functions of the myocardium and improve the quality of life of patients with diabetes mellitus. 

Aim of the study: to evaluate the significance of mean glycemic values during hospitalization as a potentially important diabetes-associated risk factor of unfavorable outcomes in inpatients with COVID-19 and type 2 diabetes mellitus (T2DM).

Materials and methods. 139 patients with COVID-19 were observed in the hospital, 42 of them had concomitant type 2 diabetes mellitus (DM2). In patients with COVID-19 and type 2 diabetes, the relationship between mean glycemic values during hospitalization and adverse outcomes (death and/or transfer of the patient to the intensive care unit (ICU)) was assessed. The average number of tests to assess glycemia in the hospital was 38.4 ± 15.68 per patient.

Results and discussion. According to correlation analysis data, an increase in mean in-hospital glycemia correlated with the severity of lung damage by computed tomography (R = 0.54, p = 0.002), the need for respiratory support by SMRT-CO score (R = 0.29, p = 0.070) and hypercoagulation by the international normalized ratio (R= –0.42, p=0.008). According to regression analysis, predictors of unfavorable outcomes included mean in-hospital glycemia (OR 1.4 [0.93; 2.12], p=0.073) and the percentage of tests with hypoglycemia in the hospital (OR 2.09 [0.89; 5 .40], p=0.016) as well as a history of diabetes (OR 5.5 [0.95, 31.60], p=0.029).

Conclusion. Impaired glycemic control during the whole hospitalization period negatively affects disease severity and the risk of adverse outcomes in patients with COVID-19 and type 2 diabetes.

The prevalence of diabetes mellitus (DM) is growing at an alarming rate worldwide. Diabetic complications are one of the leading causes of disability, morbidity and premature mortality. Along with chronic hyperglycemia, persistent systemic inflammation on the background of insulin resistance, dyslipidemia plays an important role in the development of macrovascular complications of diabetes. DM is characterized by the development of a mixed form of dyslipidemia, characterized by excessive accumulation of the most atherogenic forms of lipids. In most cases, hypertriglyceridemia occurs in type 2 diabetes. The most effective tool for correcting dyslipidemia today is fibrate therapy, including in combination with statins.

Currently, a trend towards deintensification of sugar-lowering therapy has emerged in the domestic and international clinical practice of type 2 diabetes mellitus management. And while recently reducing the intensity of antidiabetic therapy was considered primarily for elderly patients in terms of reducing the risk of hypoglycemia, it is now recognized that many other patients could benefit especially by conversion from intensive insulin therapy regimens to simpler regimens (e. g., fixed combinations of GLP-1 RA and BI). Regimen simplification and reduced number of injections have been shown to improve adherence to therapy without compromising the quality of glycemic control. 

In recent years, the importance of the concept of cardio-reno-metabolic health (CRMH) has been increasingly emphasized, reflecting the close pathogenetic and clinical relationship of cardiovascular diseases (CVD), renal dysfunction and metabolic health in general. CVD, kidney disease and type 2 diabetes mellitus (type 2 diabetes) are the key causes of high disability and mortality worldwide, and therefore cause a heavy economic burden on the health systems of all countries. Understanding the basic principles of identifying and correcting common risk factors makes it possible to identify the main strategies aimed at improving the quality and life expectancy of patients. In 2023, the American Heart Association presented updated recommendations on cardiovascular, renal and metabolic health, which describes approaches to the definition, principles of staging, prevention strategies, as well as algorithms for the treatment of cardio-reno-metabolic syndrome (CRMS). This review presents the key provisions on the management of CRMS proposed in these clinical recommendations. 

COVID-19 is a pandemic causing extreme problems in the public health system around the world. In this regard, the search for conditions associated with severe course and an increase in the death rate from COVID-19 continues to be actively conducted. Obesity creates an unfavorable background for the course of COVID-19, increasing the risk of transferring patients to the intensive care unit, the need for artificial lung ventilation and significantly affecting the mortality rate. This review presents data on the probable pathogenetic mechanisms of the effect of obesity on the course of COVID-19: restrictive disorders of the respiratory system, hyperactivation of the proinflammatory status, hypercoagulation, the role of the renin-angiotensin-aldosterone system (RAAS) and amino acid-sensitive pathways. The progressive increase in new cases of obesity requires further study of the pathogenetic mechanisms of the effect of obesity on the course of COVID-19 and the prospects for new treatment methods for these patients.

Diabetes mellitus remains one of the main socially significant health problems worldwide. Glycemic control plays a key role in the prevention of all complications of diabetes mellitus. One of the most important factors in the overall control of glycemia in patients with both type 1 and type 2 diabetes mellitus is postprandial glucose levels, as a leading risk factor for delayed vascular complications. Modern possibilities for controlling postprandial glycemia include the use of not only ultrashort insulin preparations, but also ultrafast action. One of the superfast insulin preparations available today is the drug Lumzhev ® (inLisFast), which contains lyspro insulin as an active ingredient. A number of studies on the comparative pharmacokinetics and pharmacodynamics of inLisFast compared with insulin lispro consistently demonstrate a shift in the pharmacokinetic and pharmacodynamic profile to the left, which indicates faster absorption, an increase in early insulin exposure and a decrease in late insulin exposure. inLisFast provides flexibility in the regulation of food intake, which can play a significant role in optimizing glycemic control and improving the quality of life of patients with diabetes. 

The first mention of metformin appeared about 100 years ago. Since then, the evolution of opinions about metformin has undergone significant changes. In recent decades, the active use of this drug has revealed a wide range of positive properties of metformin both in relation to metabolic health and completely unexpected aspects of longevity and quality of life. This review focuses on the current properties of metformin and the prospects for increasing the popularity of this drug among patients and medical professionals in terms of potential public health benefits.

Today, the importance of targeted cardionephroprotection is increasingly increasing as one of the vectors of a multifactorial therapeutic strategy to reduce the risk of development and progression of complications of type 2 diabetes. Pathological hyperactivation of the renin-angiotensin-aldosterone system (RAAS) and mineralocorticoid receptors (MCRs) is considered as one of the mechanisms for the development of cadiorenal syndrome (RCS) in diabetes. Blocking this pathophysiological pathway in patients with CKD and type 2 diabetes can break the vicious circle of mutually aggravating damage to the kidneys and heart. ACE inhibitors and angiotensin receptor blockers (ARBs) are currently the standard of care in patients with CRS due to diabetes. But despite their effectiveness, the residual risk of CKD progression within 4–5 years remains high in almost half of patients with type 2 diabetes, mainly due to multicomponent processes of MCR hyperactivation. This causes a range of pathological reactions affecting the entire body and may contribute to kidney, heart and CD disease in patients with type 2 diabetes by promoting inflammation and fibrosis. Functional and structural changes in the kidneys and heart develop, which leads to the development of metabolic disorders, arterial hypertension, cardiovascular complications and progressive CKD. Pharmacological blockade of aldosterone binding to MCR appears to be an effective additional line for preventing the progression of the pathological cascade of KRS reactions in type 2 diabetes. The recently developed selective non-steroidal MCR antagonist (nsAMPR) finerenone has convincingly demonstrated improved renal and cardiovascular outcomes in patients with CKD and type 2 diabetes. This review covers in detail the role of MCRs in the development of cardiorenal syndrome in type 2 diabetes and CKD, describes the mechanisms of effectiveness of MCR blockade in preventing the progression of cardiorenal syndrome in type 2 diabetes and the difference between non-steroidal MCRs and steroids, and presents the results of RCTs confirming the cardionephroprotective potential of nsAMCRs in CKD and diabetes. type 2, and the place of finerenone as a multifactorial therapeutic strategy for type 2 diabetes in clinical practice.

The antiarrhythmic drug amiodarone can affect the function of the thyroid gland, contributing to the development of thyrotoxicosis or hypothyroidism. The development of thyrotoxicosis exacerbates the cardiovascular pathology present in patients: it leads to the progression of left ventricular dysfunction, recurrence of rhythm disturbances, increasing the risk of adverse outcomes. Timely diagnosis of thyrotoxicosis in the treatment of amiodarone is of fundamental importance in choosing the right therapeutic tactics, which is determined by the type of amiodarone-induced thyrotoxicosis (AmIT), the state of the cardiovascular system, and the risk of recurrent arrhythmias. In type 1 AMIT, the main method of controlling the relief of thyrotoxicosis is thyroostatic therapy with the possibility of subsequent radical treatment (radioiodine therapy, thyroidectomy). Type 2 AmIT is a self-limiting process, however, for the treatment of patients with moderate to severe amiodarone-induced thyrotoxicosis type 2, glucocorticoids are the first-line drugs. With a mixed version of AmIT, a combination of antithyroid drugs and glucocorticoids is recommended. This review presents a clinical case of a patient with type 2 AmIT who was treated with thyrostatic drugs for a long time without achieving an effect.